Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by HENRY MARK KUERER and SAVITRI KRISHNAMURTHY.
HENRY MARK KUERER
Connection Strength
5.745
SAVITRI KRISHNAMURTHY
  1. Comment on 'Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques'. Br J Cancer. 2016 05 10; 114(10):e3.
    View in: PubMed
    Score: 0.553
  2. Feasibility of breast conserving surgery alone in HER2-positive exceptional responders to neoadjuvant systemic therapy. Eur J Surg Oncol. 2024 Aug 22; 50(12):108613.
    View in: PubMed
    Score: 0.246
  3. Nipple aspirate fluid cytology in breast carcinoma. Cancer. 2003 Apr 25; 99(2):97-104.
    View in: PubMed
    Score: 0.225
  4. Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint. J Am Coll Surg. 2023 07 01; 237(1):101-108.
    View in: PubMed
    Score: 0.222
  5. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2022 12; 23(12):1517-1524.
    View in: PubMed
    Score: 0.217
  6. Foam cells in nipple aspiration fluid. Cytopathology. 2002 Feb; 13(1):64.
    View in: PubMed
    Score: 0.206
  7. Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer. JAMA Surg. 2020 12 01; 155(12):e204103.
    View in: PubMed
    Score: 0.190
  8. Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2019 Oct; 26(10):3071-3079.
    View in: PubMed
    Score: 0.173
  9. Ductal Carcinoma In Situ and Margins <2?mm: Contemporary Outcomes With Breast Conservation. Ann Surg. 2019 01; 269(1):150-157.
    View in: PubMed
    Score: 0.167
  10. Optimal Selection of Breast Cancer Patients for Elimination of Surgery Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 12; 268(6):e61-e62.
    View in: PubMed
    Score: 0.166
  11. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 05; 267(5):946-951.
    View in: PubMed
    Score: 0.159
  12. Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer. Br J Surg. 2018 04; 105(5):535-543.
    View in: PubMed
    Score: 0.157
  13. DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. J Cancer. 2017; 8(14):2653-2662.
    View in: PubMed
    Score: 0.152
  14. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surg. 2017 07 01; 152(7):665-670.
    View in: PubMed
    Score: 0.150
  15. Paradigm Shifts in Breast Care Delivery: Impact of Imaging in a Multidisciplinary Environment. AJR Am J Roentgenol. 2017 Feb; 208(2):248-255.
    View in: PubMed
    Score: 0.144
  16. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol. 2016 Apr 01; 34(10):1072-8.
    View in: PubMed
    Score: 0.136
  17. Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. JAMA Surg. 2015 Feb; 150(2):137-43.
    View in: PubMed
    Score: 0.127
  18. Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol. 2013 Dec; 20(13):4103-12.
    View in: PubMed
    Score: 0.115
  19. Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer. Cancer Med. 2013 Apr; 2(2):226-33.
    View in: PubMed
    Score: 0.111
  20. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 2012 Jul; 13(7):688-95.
    View in: PubMed
    Score: 0.106
  21. Multidisciplinary considerations in the management of high-risk breast lesions. AJR Am J Roentgenol. 2012 Feb; 198(2):W132-40.
    View in: PubMed
    Score: 0.103
  22. Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol. 2010 Nov; 17(11):2899-908.
    View in: PubMed
    Score: 0.091
  23. A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer. Cancer. 2009 Apr 01; 115(7):1555-62.
    View in: PubMed
    Score: 0.085
  24. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009 Jan 10; 27(2):279-88.
    View in: PubMed
    Score: 0.083
  25. Breast cancer in the asian Indian population of the United States: a call for screening and education. Breast J. 2008 Jul-Aug; 14(4):402-3.
    View in: PubMed
    Score: 0.080
  26. Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer. 2006 Mar 16; 6:68.
    View in: PubMed
    Score: 0.069
  27. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat. 2005 Jan; 89(2):149-57.
    View in: PubMed
    Score: 0.063
  28. Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer. Surgery. 2004 Nov; 136(5):1061-9.
    View in: PubMed
    Score: 0.062
  29. Feasibility and utility of using chromosomal aneusomy to further define the cytologic categories in nipple aspirate fluid specimens: a preliminary study. Cancer. 2004 Oct 25; 102(5):322-7.
    View in: PubMed
    Score: 0.062
  30. Prospective evaluation of a novel approach for the use of a quantitative galactose oxidase-Schiff reaction in ductal fluid samples from women with breast carcinoma. Cancer. 2004 Jun 15; 100(12):2549-54.
    View in: PubMed
    Score: 0.061
  31. Patient Interest in Exploring Nonsurgical Treatment Approaches for Early-Stage Breast Cancer: A Qualitative Study. Int J Radiat Oncol Biol Phys. 2024 Feb 01; 118(2):443-454.
    View in: PubMed
    Score: 0.058
  32. Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy: A Nonrandomized Clinical Trial. JAMA Netw Open. 2023 09 05; 6(9):e2333933.
    View in: PubMed
    Score: 0.058
  33. High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer. Clin Cancer Res. 2003 Feb; 9(2):601-5.
    View in: PubMed
    Score: 0.055
  34. Identification of distinct protein expression patterns in bilateral matched pair breast ductal fluid specimens from women with unilateral invasive breast carcinoma. High-throughput biomarker discovery. Cancer. 2002 Dec 01; 95(11):2276-82.
    View in: PubMed
    Score: 0.055
  35. Characterization of foam cells in nipple aspirate fluid. Diagn Cytopathol. 2002 Nov; 27(5):261-4; discussion 265.
    View in: PubMed
    Score: 0.054
  36. Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma. Cancer. 2002 Sep 01; 95(5):982-8.
    View in: PubMed
    Score: 0.054
  37. Important technical considerations for skin-sparing mastectomy with sentinel lymph node dissection. Arch Surg. 2002 Jun; 137(6):747.
    View in: PubMed
    Score: 0.053
  38. Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients. Ann Surg Oncol. 2021 Aug; 28(8):4277-4283.
    View in: PubMed
    Score: 0.048
  39. Feasibility of fine-needle aspiration for assessing responses to chemotherapy in metastatic nodes marked with clips in breast cancer: A prospective registry study. Cancer. 2019 02 01; 125(3):365-373.
    View in: PubMed
    Score: 0.041
  40. Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints. Ann Surg Oncol. 2018 Jul; 25(7):1953-1960.
    View in: PubMed
    Score: 0.040
  41. Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast?Cancer. Clin Breast Cancer. 2018 02; 18(1):e73-e77.
    View in: PubMed
    Score: 0.038
  42. Radiologic Mapping for Targeted Axillary Dissection: Needle Biopsy to Excision. AJR Am J Roentgenol. 2016 Dec; 207(6):1372-1379.
    View in: PubMed
    Score: 0.036
  43. Confocal fluorescence microscopy to evaluate changes in adipocytes in the tumor microenvironment associated with invasive ductal carcinoma and ductal carcinoma in situ. Int J Cancer. 2016 09 01; 139(5):1140-9.
    View in: PubMed
    Score: 0.035
  44. Microcalcifications in 1657 Patients with Pure Ductal Carcinoma in Situ of the Breast: Correlation with Clinical, Histopathologic, Biologic Features, and Local Recurrence. Ann Surg Oncol. 2016 Feb; 23(2):482-9.
    View in: PubMed
    Score: 0.033
  45. Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. J Natl Cancer Inst. 2015 Nov; 107(11).
    View in: PubMed
    Score: 0.033
  46. Micro-anatomical quantitative optical imaging: toward automated assessment of breast tissues. Breast Cancer Res. 2015 Aug 20; 17:105.
    View in: PubMed
    Score: 0.033
  47. Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ? Ann Surg Oncol. 2015 Dec; 22(13):4270-9.
    View in: PubMed
    Score: 0.032
  48. Correlation between sonographic findings and clinicopathologic and biologic features of pure ductal carcinoma in situ in 691 patients. AJR Am J Roentgenol. 2015 Apr; 204(4):878-88.
    View in: PubMed
    Score: 0.032
  49. Circulating tumor cells in non-metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2014 Sep; 147(2):325-33.
    View in: PubMed
    Score: 0.031
  50. Predicting the extent of nodal disease in early-stage breast cancer. Ann Surg Oncol. 2014 Oct; 21(11):3440-7.
    View in: PubMed
    Score: 0.030
  51. Implementation of the american college of surgeons oncology group z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy? Ann Surg Oncol. 2014 Aug; 21(8):2468-73.
    View in: PubMed
    Score: 0.030
  52. Feasibility of confocal fluorescence microscopy for real-time evaluation of neoplasia in fresh human breast tissue. J Biomed Opt. 2013 Oct; 18(10):106016.
    View in: PubMed
    Score: 0.029
  53. Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status. Breast Cancer Res Treat. 2013 Jun; 139(3):639-47.
    View in: PubMed
    Score: 0.028
  54. Invasive lobular carcinoma predicts micrometastasis in breast cancer. J Surg Res. 2012 Sep; 177(1):93-6.
    View in: PubMed
    Score: 0.026
  55. Epstein-Barr virus is seldom found in mammary epithelium of breast cancer tissue using in situ molecular methods. Breast Cancer Res Treat. 2012 Feb; 132(1):267-74.
    View in: PubMed
    Score: 0.025
  56. Prospective evaluation of the nipple-areola complex sparing mastectomy for risk reduction and for early-stage breast cancer. Ann Surg Oncol. 2012 Apr; 19(4):1137-44.
    View in: PubMed
    Score: 0.025
  57. Limited evidence of human papillomavirus in [corrected] breast tissue using molecular in situ methods. Cancer. 2012 Mar 01; 118(5):1212-20.
    View in: PubMed
    Score: 0.025
  58. Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer. Cancer. 2012 Jan 15; 118(2):342-8.
    View in: PubMed
    Score: 0.025
  59. Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. Ann Surg Oncol. 2010 Dec; 17(12):3252-8.
    View in: PubMed
    Score: 0.023
  60. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer. 2010 Jun 01; 116(11):2543-8.
    View in: PubMed
    Score: 0.023
  61. Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg. 2008 Jul; 196(1):81-7.
    View in: PubMed
    Score: 0.020
  62. Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol. 2006 Mar; 13(3):310-20.
    View in: PubMed
    Score: 0.017
  63. Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. Clin Cancer Res. 2005 Dec 01; 11(23):8312-20.
    View in: PubMed
    Score: 0.017
  64. Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma. Cancer. 2004 Sep 15; 101(6):1330-7.
    View in: PubMed
    Score: 0.015
  65. Feasibility of breast-conserving surgery for patients with breast carcinoma associated with nipple discharge. Cancer. 2004 Aug 01; 101(3):508-17.
    View in: PubMed
    Score: 0.015
  66. Impact of clinicopathological factors on sensitivity of axillary ultrasonography in the detection of axillary nodal metastases in patients with breast cancer. Ann Surg Oncol. 2003 Nov; 10(9):1025-30.
    View in: PubMed
    Score: 0.015
  67. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol. 2003 Apr; 10(3):248-54.
    View in: PubMed
    Score: 0.014
  68. Histologic localization of sentinel lymph node metastases in breast cancer. Am J Surg Pathol. 2003 Mar; 27(3):385-9.
    View in: PubMed
    Score: 0.014
  69. Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer. 2003 Feb 15; 97(4):926-33.
    View in: PubMed
    Score: 0.014
  70. Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. Cancer. 2002 Nov 15; 95(10):2059-67.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.